Suppr超能文献

纤维化、再生与癌症:它们之间有何关联?

Fibrosis, regeneration and cancer: what is the link?

机构信息

Division of Nephrology, Department of Internal Medicine, University of Messina, Messina, Italy.

出版信息

Nephrol Dial Transplant. 2012 Jan;27(1):21-7. doi: 10.1093/ndt/gfr567. Epub 2011 Nov 18.

Abstract

Tubulo-interstitial fibrosis constitutes the final common pathway for all pathological conditions that evolve towards chronic kidney disease, and transforming growth factor-β1 plays a key role in this process. Furthermore, neutrophil gelatinase-associated lipocalin appears not only to be a simple marker of renal injury but also an active player in disease progression. We are not yet able to control and modulate this phenomenon. Therefore, a better understanding of fibrogenic molecular mechanisms is necessary to detect possible therapeutic strategies that interfere with fibrosis and then stop the progression of renal disease. The line of research called 'regenerative medicine' works toward this. According to many authors, the formation of a fibrotic extracellular matrix disrupts the cells' polarity and stimulates their proliferation, creating conditions for cancer development. However, there is another plausible hypothesis: is it possible that fibrosis provides a sort of 'protection' from the development of a cancer as a consequence of the intense proliferation that characterizes any inflammatory process? In superior organisms, and also in humans, regeneration may have been selected negatively and replaced by fibrosis in the course of evolution, to warrant species survival: in fact, unchecked pluripotent cell production and proliferation can lead to tumour development and the potential death of a single individual. Hence, tumours might be the outcome of the failure of fibrotic processes, most likely due to some mediators predominating over others. So, valid experimental models are necessary to understand the interactions that exist between fibrosis and tumours and to evaluate the real advantage of therapies that aim to inhibit the fibrotic process at the renal level or that of other organs. The ideal approach would be to limit fibrosis and then organ function loss but without exposing the patient to risks of developing a tumour, starting from as early as the drugs prescribed.

摘要

肾小管-间质纤维化是所有向慢性肾脏病进展的病理状态的共同最终途径,而转化生长因子-β1 在这个过程中起着关键作用。此外,中性粒细胞明胶酶相关脂质运载蛋白似乎不仅是肾脏损伤的简单标志物,而且也是疾病进展的积极参与者。我们还不能控制和调节这种现象。因此,需要更好地了解纤维化的分子机制,以发现可能的治疗策略,从而干扰纤维化并阻止肾脏疾病的进展。所谓的“再生医学”就是朝着这个方向努力的。根据许多作者的观点,纤维化的细胞外基质的形成破坏了细胞的极性并刺激其增殖,为癌症的发展创造了条件。然而,还有另一种合理的假设:纤维化是否为癌症的发展提供了一种“保护”,因为任何炎症过程的特征性强烈增殖?在高等生物中,甚至在人类中,再生可能在进化过程中被消极选择,被纤维化所取代,以保证物种的生存:事实上,不受控制的多能细胞产生和增殖可能导致肿瘤的发展和单个个体的潜在死亡。因此,肿瘤可能是纤维化过程失败的结果,最有可能是由于某些介质占主导地位。因此,需要有效的实验模型来理解纤维化和肿瘤之间存在的相互作用,并评估旨在抑制肾脏或其他器官纤维化过程的治疗方法的真正优势。理想的方法是限制纤维化,然后是器官功能丧失,但又不使患者面临发展肿瘤的风险,从一开始就从开的药物着手。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验